Cargando…
Immune checkpoint blockade therapy for bladder cancer treatment
Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune checkpoints have been recently been applied to many aggressive cancers and changed interventions of urol...
Autor principal: | Kim, Jayoung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910761/ https://www.ncbi.nlm.nih.gov/pubmed/27326412 http://dx.doi.org/10.4111/icu.2016.57.S1.S98 |
Ejemplares similares
-
Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020) -
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
por: Cheng, Wen, et al.
Publicado: (2018) -
The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018) -
Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020) -
Microbial biomarkers for immune checkpoint blockade therapy against cancer
por: Adachi, Keishi, et al.
Publicado: (2018)